Brown Advisory Inc. Raises Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Brown Advisory Inc. boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 570,258 shares of the company's stock after acquiring an additional 14,049 shares during the quarter. Brown Advisory Inc. owned 0.44% of Vaxcyte worth $21,533,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PCVX. Smartleaf Asset Management LLC boosted its holdings in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the period. National Bank of Canada FI purchased a new position in Vaxcyte in the fourth quarter valued at $41,000. Parallel Advisors LLC boosted its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after purchasing an additional 1,071 shares during the period. Assetmark Inc. boosted its holdings in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares during the period. Finally, J.Safra Asset Management Corp lifted its holdings in Vaxcyte by 65.8% during the 1st quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company's stock worth $119,000 after buying an additional 1,254 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Bank of America decreased their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Vaxcyte in a report on Tuesday, April 22nd. They set an "overweight" rating for the company. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Finally, The Goldman Sachs Group decreased their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Down 0.9%

PCVX stock traded down $0.31 during trading on Friday, hitting $35.93. The company had a trading volume of 1,947,376 shares, compared to its average volume of 1,492,086. The firm has a market cap of $4.64 billion, a PE ratio of -9.01 and a beta of 1.19. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The firm has a 50-day moving average price of $33.31 and a 200-day moving average price of $55.25.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the business posted ($0.85) earnings per share. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.